Shield Therapeutics - Edison Group

Overview
Price performance
Financials
Research
Thematics

Latest Insights

View More

Healthcare |
Flash note

11.01.24

Shield Therapeutics — New CFO to support US traction

Healthcare |
Flash note

08.12.23

Shield Therapeutics — Delivering what the doctor ordered

Healthcare |
Update

29.09.23

Shield Therapeutics — Ramped up and heading into a stronger H223

Healthcare |
Update

04.05.23

Shield Therapeutics — FY23 a key year for business traction

Laboratory

Sector

Healthcare

Balance Sheet

Forecast net debt (US$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(37.6)	(79.1)	(73.3)
Relative	(39.7)	(79.9)	(74.1)
52 week high/low	12.5p/1.6p

Financials

Shield Therapeutics has appointed Santosh Shanbhag as chief financial officer (CFO) and member of the executive leadership team. Mr. Shanbhag was previously the CFO of Nasdaq-listed Akili, which he helped grow and take public. Before Akili, he held senior finance positions at Vertex Pharmaceuticals, where he worked on business and corporate development and helped secure reimbursement for novel drugs in key international markets. We expect Shield to leverage Mr. Shanbhag’s US healthcare experience, which should support the company in optimising pricing and expand payor coverage for Accrufer.

Y/E Dec	Revenue (US$m)	EBITDA (US$m)	PBT (US$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2021A	N/A	N/A	N/A	N/A	N/A	N/A
2022A	5.5	(28.7)	(31.2)	(12.3)	N/A	N/A
2023E	N/A	N/A	N/A	N/A	N/A	N/A
2024E	N/A	N/A	N/A	N/A	N/A	N/A

Research

Update

Healthcare

23.08.21

Shield Therapeutics — 2021 focus on Accrufer

Flash note

Healthcare

28.05.21

Shield Therapeutics — Greg Madison succeeds Tim Watts as CEO

Healthcare

Flash note

Shield Therapeutics — Operating results eclipsed by financing difficulties

Update

Healthcare

04.05.21

Shield Therapeutics — 2021 all eyes on Accrufer US launch

Update

Healthcare

05.03.21

Shield Therapeutics — Accrufer coming to America

Outlook

Healthcare

01.02.21

Shield Therapeutics — Beefing up for the US opportunity

Update

Healthcare

11.12.20

Shield Therapeutics — Close but no cigar

Update

Healthcare

18.09.20

Shield Therapeutics — US partner next major inflection point

Flash note

Healthcare

07.08.20

Shield Therapeutics — AEGIS-H2H update – non-inferiority at 24 weeks

Update

Healthcare

22.05.20

Shield Therapeutics — All eyes on a US partnering deal

Update

Healthcare

04.05.20

Shield Therapeutics — Next step a US partnering deal

Flash note

Healthcare

22.04.20

Shield Therapeutics — Tim Watts succeeds Carl Sterritt as CEO

Flash note

Healthcare

18.03.20

Shield Therapeutics — AEGIS-2 update

Update

Healthcare

27.01.20

Shield Therapeutics — 2019 a landmark year

Update

Healthcare

13.01.20

Shield Therapeutics — Feraccru out-licensed in China

Update

Healthcare

08.08.19

Shield Therapeutics — The land of opportunity awaits Accrufer

Update

Healthcare

26.07.19

Shield Therapeutics — FDA approval attained, sales execution now key

edison tv

Healthcare

09.07.19

Bitesize briefing – Shield Therapeutics

Update

Healthcare

03.04.19

Shield Therapeutics — Next step US Feraccru approval

edison tv

Healthcare

25.03.19

Executive interview – Shield Therapeutics

Update

Healthcare

04.03.19

Shield Therapeutics — Feraccru performs again in a Phase III study

Initiation

Healthcare

19.02.19

Shield Therapeutics — Fortified for growth